References in periodicals archive ?
In: Acute and chronic myeloproliferative disorders and myelodysplasia.
According to Dameshek, true polycythemia (polycythemia vera: PV) is a chronic myeloproliferative disorder of the total bone marrow without any evidence of invasiveness, in which erythrocytosis, leukocytosis, and thrombocytosis are all simultaneously present.
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.
ORLANDO -- Thrombosis was significantly more prevalent in women, compared with men, in a review of data from 270 adults with JAK2 V617-F-positive myeloproliferative disorder, according to a poster at the meeting.
Chronic myeloproliferative disorders (CMPDs) are clonal haematopoietic stem cell disorders and include the BCR-ABL negative CMPDs like polycythemia vera (PV), essential thrombocythemia (ET), idiopathic myelofibrosis (IMF) and chronic eosinophilic leukaemia (CEL) (1,2).
Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009.
Coverage includes techniques for the detection of BCR-ABL mutations and resistance to imatinib mesylate, detection of the FIP 1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia, classification of acute myeloid leukemia by DNA- oligonucleotide microarrays, detection of the V617F JAK2 mutation in myeloproliferative disorders, gene rearrangements, FLT3 mutations andWT-1 overexpression.
Platelet dysfunction is associated with many systemic disorders, such as renal disease, hepatic failure, connective tissue disorders, myeloproliferative disorders, myelodysplastic disorders, malignancy, and cardiovascular disease.
This report provides information on the therapeutic development for Myeloproliferative Disorders, complete with latest updates, and special features on late-stage and discontinued projects.
List Professor of Medicine, Director of Myeloproliferative Disorders Research Program at the Tisch Cancer Institute at Mount Sinai.
To establish a diagnosis of ET, reactive causes of thrombocytosis should be absent and other chronic myeloproliferative disorders should be ruled out (1).
The myeloproliferative neoplasms (MPN), formerly known as the myeloproliferative disorders (MPD), are a group of clonal disorders involving hyperproliferation of one or more of the myeloid cell lines (erythrocytic, granulocytic, megakaryocytic).